Aggregated α-synuclein plays an important role in Parkinson's disease pathogenesis. Cinpanemab, a human-derived monoclonal antibody that binds to α-synuclein, is being evaluated as a disease-modifying treatment for Parkinson's disease.
Trial of Cinpanemab in Early Parkinson's Disease
Zappia, MarioMembro del Collaboration Group
2022-01-01
Abstract
Aggregated α-synuclein plays an important role in Parkinson's disease pathogenesis. Cinpanemab, a human-derived monoclonal antibody that binds to α-synuclein, is being evaluated as a disease-modifying treatment for Parkinson's disease.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Trial of cinpanemab...pdf
accesso aperto
Tipologia:
Versione Editoriale (PDF)
Dimensione
602.63 kB
Formato
Adobe PDF
|
602.63 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
